Meropenem is a carbapenem antibiotic. It is active against clinical isolates of Gram-positive and Gram-negative bacteria in vitro, including S. pneumoniae, H. influenzae, N. gonorrhoeae, E. coli, P. aeruginosa, C. difficile, and methicillin-susceptible and -resistant S. aureus (MICs = ≤0.008-8 μg/ml). It is protective against S. aureus, S. pneumoniae, E. coli, S. marcescens, P. mirabilis, and P. aeruginosa infections in mice with 50% protective dose (PD50) values of 0.13, 0.01, 0.04, 0.07, 0.84, and 0.46 mg/kg, respectively. Formulations containing meropenem have been used in the treatment of a variety of bacterial infections.
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.